Abiola Ibraheem

560 total citations
26 papers, 364 citations indexed

About

Abiola Ibraheem is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Abiola Ibraheem has authored 26 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Cancer Research. Recurrent topics in Abiola Ibraheem's work include Advances in Oncology and Radiotherapy (5 papers), Breast Cancer Treatment Studies (5 papers) and Ethics in Clinical Research (4 papers). Abiola Ibraheem is often cited by papers focused on Advances in Oncology and Radiotherapy (5 papers), Breast Cancer Treatment Studies (5 papers) and Ethics in Clinical Research (4 papers). Abiola Ibraheem collaborates with scholars based in United States, Nigeria and United Kingdom. Abiola Ibraheem's co-authors include Olufunmilayo I. Olopade, Dezheng Huo, David J. Press, Blasé N. Polite, Wei Peng Yong, Cody J. Peer, Chadi Nabhan, Walter M. Stadler, Edmund Chiong and Bradley Curtis Carthon and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Abiola Ibraheem

21 papers receiving 359 citations

Peers

Countries citing papers authored by Abiola Ibraheem

Since Specialization

Citations

This map shows the geographic impact of Abiola Ibraheem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abiola Ibraheem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abiola Ibraheem more than expected).

Fields of papers citing papers by Abiola Ibraheem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abiola Ibraheem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abiola Ibraheem. The network helps show where Abiola Ibraheem may publish in the future.

Co-authorship network of co-authors of Abiola Ibraheem

This figure shows the co-authorship network connecting the top 25 collaborators of Abiola Ibraheem. A scholar is included among the top collaborators of Abiola Ibraheem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abiola Ibraheem. Abiola Ibraheem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Anti-cancer chlorambucil drug delivery by Pt, au, and Ir-decorated ZnO nanotubes 2025 ·Solid State Communications ·Yousef A. Bin Jardan, (unknown), Mohammed Ahmed Mustafa, (unknown), Suhas Ballal, (unknown), (unknown), (unknown), Abiola Ibraheem, Mounir M. Salem‐Bekhit, Ahmed M. Naglah	0
2	Global Equity in Clinical Trials: An ASCO Policy Statement 2024 ·JCO Global Oncology ·Sana Al‐Sukhun, Verna Vanderpuye, Carolyn Taylor, Abiola Ibraheem, (unknown), Fredrick Chite Asirwa, Michael Francisco, (unknown)	7
3	Examining Cancer Patients' Perceptions of the Impact of COVID-19 on Teleoncology: Findings From 15 Nigerian Outpatient Cancer Clinics 2023 ·JCO Global Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Abiola Ibraheem, Omolara Fatiregun, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Mohammad Rifat Haider, Bankole Olatosi, (unknown), Adedayo A. Onitilo	0
4	Association of Social Determinants and Tumor Biology With Racial Disparity in Survival From Early-Stage, Hormone-Dependent Breast Cancer 2023 ·JAMA Oncology ·Kent Hoskins, Gregory S. Calip, Hsiao‐Ching Huang, Abiola Ibraheem, Oana C. Danciu, Garth H. Rauscher	27
5	Abstract PD7-06: Unstable mutational profile and heterogeneity of residual breast tumor following neoadjuvant therapy from comprehensive genomic and transcriptomic sequencing 2021 ·Cancer Research ·Minoru Miyashita, Masaya Hattori, Yonglan Zheng, Toshio F. Yoshimatsu, Joshua S. K. Bell, Padma Sheila Rajagopal, Anna Woodard, (unknown), (unknown), Galina Khramtsova, Fang Liu, Abiola Ibraheem, Gini F. Fleming, Nora Jaskowiak, Rita Nanda, (unknown), Nike Beaubier, Kevin P. White, Dezheng Huo, Olufunmilayo I. Olopade	0
6	Abstract SS1-06: Racial disparities in pathological complete response among breast cancer patients receiving neoadjuvant chemotherapy 2021 ·Cancer Research ·Fangyuan Zhao, (unknown), Abiola Ibraheem, Gini F. Fleming, Nora Jaskowiak, Rita Nanda, Olufunmilayo I. Olopade, Dezheng Huo	1
7	Consensus molecular subtyping of colorectal cancer by immunohistochemistry, an imperative for a resource limited setting 2021 ·FB Abdulkareem, Galina Khramtsova, (unknown), (unknown), (unknown), Olorunda Rotimi, Abiola Ibraheem, Andrey Khramtsov, Lise Sveen, Ian Hurley, Masaya Hattori, Dezheng Huo, (unknown)	0
8	Breast Cancer Research to Support Evidence-Based Medicine in Nigeria: A Review of the Literature 2021 ·JCO Global Oncology ·Omolara Fatiregun, (unknown), (unknown), (unknown), Abiola Ibraheem, Olufunmilayo I. Olopade	4
9	Implementing oncology clinical trials in Nigeria: a model for capacity building 2020 ·BMC Health Services Research ·Atara Ntekim, Abiola Ibraheem, (unknown), (unknown), Mojisola Oluwasanu, Toyin Aniagwu, Olutosin Awolude, Williams Balogun, (unknown), Prisca Olabisi Adejumo, Chinedum P. Babalola, Ganiyu Olatunbosun Arinola, Oladosu Ojengbede, Christopher O. Olopade, Olufunmilayo I. Olopade	11
10	Racial disparities in survival outcomes among breast cancer patients by molecular subtypes 2020 ·Breast Cancer Research and Treatment ·Fangyuan Zhao, (unknown), Qun Niu, Fang Liu, Julie A. Johnson, Thomas L. Sutton, Galina Khramtsova, (unknown), Toshio F. Yoshimatsu, Yonglan Zheng, Abiola Ibraheem, Nora Jaskowiak, Rita Nanda, Gini F. Fleming, Olufunmilayo I. Olopade, Dezheng Huo	26
11	Comparison of Public-Private Partnership and Federally Sponsored Radiotherapy Facilities in Nigeria 2020 ·International Journal of Radiation OncologyBiologyPhysics ·Chidinma P. Anakwenze, Surbhi Grover, Abiola Ibraheem, Ann H. Klopp, Anuja Jhingran, Lilie L. Lin, Jim Leng, (unknown), Kathleen M. Schmeler, Atara Ntekim	1
12	Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base 2020 ·Cancer ·Abiola Ibraheem, Olufunmilayo I. Olopade, Dezheng Huo	32
13	ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol 2020 ·JCO Global Oncology ·Atara Ntekim, Abiola Ibraheem, (unknown), (unknown), Chinedum P. Babalola, Theodore Karrison, Christopher O. Olopade	2
14	Infrastructural Challenges Lead to Delay of Curative Radiotherapy in Nigeria 2020 ·JCO Global Oncology ·Jim Leng, Atara Ntekim, Abiola Ibraheem, Chidinma P. Anakwenze, Daniel W. Golden, Olufunmilayo I. Olopade	25
15	Survey of medical student knowledge in oncology and survivorship care in Nigeria: A pilot study. 2019 ·Journal of Clinical Oncology ·Jim Leng, Abiola Ibraheem, Atara Ntekim, Abiodun Popoola, (unknown), (unknown), Daniel W. Golden, Olufunmilayo I. Olopade	0
16	Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy? 2018 ·Cancer ·Abiola Ibraheem, David J. Press, Olufunmilayo I. Olopade, Dezheng Huo	25
17	Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer 2018 ·Journal of Clinical Oncology ·Russell Z. Szmulewitz, Cody J. Peer, Abiola Ibraheem, (unknown), Mark Kozloff, Bradley Curtis Carthon, R. Donald Harvey, Paul A. S. Fishkin, Wei Peng Yong, Edmund Chiong, Chadi Nabhan, Theodore Karrison, William D. Figg, Walter M. Stadler, Mark J. Ratain	116
18	Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results 2017 ·Breast Cancer Research and Treatment ·David J. Press, Abiola Ibraheem, M. Eileen Dolan, Kathleen H. Goss, Suzanne D. Conzen, Dezheng Huo	27
19	Formal assessment of teamwork among cancer health care professionals in 3 large tertiary centers in Nigeria. 2017 ·Journal of Clinical Oncology ·Abiola Ibraheem, Olutosin Awolude, (unknown), (unknown), (unknown), Olufunmilayo I. Olopade, Blasé N. Polite	1
20	A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC). 2017 ·Journal of Clinical Oncology ·Russell Z. Szmulewitz, Abiola Ibraheem, Cody J. Peer, William D. Figg, Bradley Curtis Carthon, Mark Kozloff, Donald Harvey, Paul A. S. Fishkin, Wei Peng Yong, Edmund Chiong, Chadi Nabhan, Peter H. O’Donnell, Walter M. Stadler, Mark J. Ratain	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact